Welcome to Wilyer – your trusted partner in revolutionizing digital communication. We aim to empower businesses to connect with their audiences dynamically and engagingly.At Wilyer, we bridge the gap between static communication and interactive experiences, helping businesses grow and thrive. Our Vision: We envision a future where Wilyer is the leading global platform for cloud-based digital signage solutions. Our goal is to seamlessly integrate into any business environment, transforming how companies communicate with their audiences. We aspire to: > Lead the digital signage software market. > Achieve global recognition. > Ensure seamless integration into diverse business settings. > Revolutionize communication through innovative digital signage. Our long-term ambitions include developing cutting-edge features like AI-powered content creation, partnering with hardware manufacturers, and offering industry-specific solutions to meet unique business needs.
STORK RUBBER PRODUCTS PVT. LTD.
Established in 1995, Stork began manufacturing in 1996 with 3 employees and 200 sq. ft. of production area. As of 2023, the Stork Group comprises 2 companies with 500 employees across 4 manufacturing locations, spanning 275,000 sq. ft. Our 2 warehouses located in North America help to seamlessly support our deliveries to OEM customers in that region. We are dedicated to manufacturing excellence, serving the Automotive, Industrial, and Power Transmission sectors.
Sterlite Electric
Sterlite Electric Ltd is a manufacturer of capital goods and a provider of system integration solutions, specializing in the power T&D industry for both domestic and international markets. Its product portfolio includes a wide range of overhead conductors, power cables, optical ground wire, along with master system integration services.
SPHAERA PHARMA
Sphaera is a drug discovery and development biotech, led by a team with extensive life sciences experience. We have successfully created value for our partners, collaborators and patients by advancing multiple preclinical projects into the clinic. Sphaera Pharma is committed to provide innovative therapeutics to those who need it the most. – Sphaera through its embedded collaborations, has access to global technologies and capabilities across the drug discovery & development spectrum. Innovative platform technologies and discovery experience makes us an ideal partner for young biotechs, academic spinouts and researchers who are driven to challenge the norms of conventional discovery – Scalable preclinical R&D capabilities under a single roof, with service experience and potential for new collaborations with virtual biotechs
Sona BLW Precision Forgings Ltd
Sona Comstar is one of the world’s leading automotive technology companies. Sona Comstar is headquartered in India. We primarily design, manufacture, and supply highly engineered, mission-critical automotive systems and components to automotive OEMs. We are a leading supplier to the fast-growing global Electric Vehicle Market.
SKIPPERSEIL LIMITED
Since 1986 SkipperSeil Ltd is one of the leading exporter of Power Transformers upto 500MVA/ 765kV in India having ISO 9001, ISO 14001 and ISO 45001 certified manufacturing plant based out of Bhiwadi, Rajasthan. The facility is equipped with state-of-the-art machinery and NABL accredited, fully computerised sophisticated test laboratory to manufacture transformers of various designs to suit customer requirements as per IS, IEC, ANSI and other International Standards. Our government (DSIR) recognised R&D Centre manned by team of specialist and professionals is well known for its achievements. The company also make transformers for special applications like furnace, rectifiers, Traction, Solar and locomotives. SkipperSeil Power Transformer are well known for their quality, reliability and dependability, even under tough environmental conditions and are operating satisfactorily in many countries for over the last four decades.
Premas Biotech
Premas Biotech, based in Gurgaon, India, is a leading Contract Development and Manufacturing organization (CDMO) with 19 years of expertise. Specializing in protein delivery and therapeutic/vaccine development, Premas has successfully delivered over 750 proteins to more than 50 satisfied customers. Our partnerships span developed markets with multiple molecules in the clinical pipeline. Key Highlights: Quality and Compliance: Recognized as a DSIR “In-house Research & Development Unit” and ISO 9001:2015 certified by TUV SUD. Our GMP manufacturing facility is accredited by CDSCO (India) and audited by regulatory bodies from China, Israel, and the US FDA. We adhere strictly to SOPs, STPs, and maintain a robust Quality policy focused on high-quality product delivery. Customer-Centric Approach: Known for flexibility, on-time deliveries, cost reduction, and strong analytical development. We prioritize customer delight through continuous learning, integrity, ownership, and creativity. Process Excellence: Implementing lean manufacturing principles (Toyota Production System), we enhance efficiencies in project management and execution. Our scientific and project management strengths ensure successful process development and material supply for preclinical and clinical studies. Innovative Solutions: Expertise in expression and purification of proteins to meet IND filing specifications for biotherapeutic and vaccine candidates. We ensure robust scale-up, tech transfer, and clinical trial material supply using our GMP-compliant facility. Premas Biotech is committed to enabling quicker, more secure, and cost-effective therapeutic/vaccine development. We value interactive collaboration and welcome feedback to continuously improve our processes and outcomes. | Premas Biotech was founded with a singular mission: to enable the advancement of biologics by solving the challenge of producing difficult-to-express proteins. For over 20 years, Premas has built a differentiated capability stack across bacterial, yeast, and mammalian expression systems, supporting global partners from gene to clinic. Our integrated platform combines expression engineering, process development, analytical characterization, scale-up, and GMP manufacturing to accelerate timelines while reducing technical risk and cost of goods. At the core of Premas’ innovation engine is its proprietary D-Crypt™ platform, an engineered yeast-based system designed to express complex and membrane proteins that are traditionally intractable. This platform has enabled the successful delivery of 900+ proteins and multiple tech-transferred programs, positioning Premas as a strategic partner for next-generation biologics and vaccine development. We have expanded this foundation into a technology-driven vaccine development portfolio spanning recombinant antigens, virus-like particles (VLPs), circRNA-VLP constructs, and glycoconjugate carrier proteins. Our pipeline includes a first-in-class triple-antigen VLP vaccine candidate against SARS-CoV-2 that has completed Phase I clinical trials, alongside additional in-house programs targeting influenza, RSV, and other infectious diseases. With over 30 vaccine development programs executed across human and animal health, Premas delivers end-to-end, tech-transfer-ready solutions from design through GMP manufacturing. Complementing our biologics and vaccine platforms, we have developed AXTEX-4D™, a proprietary ex vivo 3D tissueoid platform that enables human-relevant disease modeling. Designed to better replicate in vivo tumor microenvironments, AXTEX-4D™ supports advanced applications across drug discovery, efficacy testing, and translational research, with compatibility across standard biological and analytical assays. By integrating protein engineering, platform-based vaccine development, and predictive human biology systems, we offer a unified, scalable engine to accelerate biologics innovation—bridging discovery, development, and clinical translation for global partners.